We serve Chemical Name:2-amino-4-oxo-1H-pyrimidine-6-carboxylic acid CAS:6973-52-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-amino-4-oxo-1H-pyrimidine-6-carboxylic acid
CAS.NO:6973-52-0
Synonyms:2-Amino-4-hydroxy-pyrimidin-carbonsaeure-(6);2-Amino-6-hydroxy-pyrimidin-carbonsaeure-(4);2-Aminoorotic acid;2-amino-4-hydroxypyrimidine-6-carboxylic acid;2-amino-6-hydroxypyrimidine-4-carboxylic acid;2-amino-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid
Molecular Formula:C5H5N3O3
Molecular Weight:155.11100
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:365.5ºC at 760 mmHg
Density:1.88g/cm3
Index of Refraction:1.75
PSA:109.07000
Exact Mass:155.03300
LogP:
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-Amino-4-hydroxy-pyrimidin-carbonsaeure-(6) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-amino-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-amino-6-oxo-1,6-dihydro-pyrimidine-4-carboxylic acid Use and application,2-Amino-6-hydroxy-pyrimidin-carbonsaeure-(4) technical grade,usp/ep/jp grade.
Related News: Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System. 2-amino-4-oxo-1H-pyrimidine-6-carboxylic acid manufacturer Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System. 2-amino-4-oxo-1H-pyrimidine-6-carboxylic acid supplier Further research on Oligomannate��s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement. 2-amino-4-oxo-1H-pyrimidine-6-carboxylic acid vendor Right now, midstage data for Roche-AC Immune’s anti-tau antibody semorinemab in moderate Alzheimer’s are expected later this year, but it has already failed a phase 2 study in mild disease. 2-amino-4-oxo-1H-pyrimidine-6-carboxylic acid factory There is fierce competition for bulk APIs and overcapacity. However, some high-profit, small-scale drugs still have a good market space.
